{{scheme.chgp}}%
{{scheme.chgp}}%
No Matches Found
{{scheme.chgp}}%
No Matches Found
No Matches Found
Neurocrine Biosciences, Inc.
Neurocrine Biosciences Hits New 52-Week High at $181.02
Neurocrine Biosciences, Inc. has achieved a new 52-week high, reflecting its strong performance with a 31.48% return over the past year. The company, with a market cap of USD 12,879 million, is net-debt-free and shows impressive growth metrics, including significant increases in net sales and operating profit.
Neurocrine Biosciences Hits New 52-Week High of $171.24
Neurocrine Biosciences, Inc. has achieved a new 52-week high, reflecting its strong performance with a 25.12% annual increase. The company boasts impressive financial metrics, including a 14.97% return on equity and significant growth in net sales and profit, while maintaining a net-debt-free status.
Neurocrine Biosciences Experiences Revision in Stock Evaluation Amid Market Dynamics
Neurocrine Biosciences, Inc. has seen a stock price decline to $128.32, with a year-to-date return of 12.56%. Despite recent bearish technical indicators, the company has demonstrated strong long-term performance, achieving a 263.20% return over the past decade, surpassing the S&P 500's 207.36%.
Neurocrine Biosciences Experiences Evaluation Revision Amid Mixed Market Performance Indicators
Neurocrine Biosciences, Inc. has recently revised its evaluation amid changing market conditions. The company's stock price is currently $129.64, reflecting a year-to-date return of 13.87%, which is below the S&P 500's 18.89%. Technical indicators present a mixed outlook, with varying trends across different time frames.
Neurocrine Biosciences Forms Death Cross, Signaling Potential Bearish Trend
Neurocrine Biosciences, Inc. has recently encountered a Death Cross, indicating a potential shift in market sentiment. Technical indicators present a mixed outlook, with a bearish weekly MACD and a bullish monthly perspective. Year-to-date, the stock has declined 6.66%, underperforming the S&P 500's modest gain.
Neurocrine Biosciences Experiences Revision in Its Stock Evaluation Amid Strong Financial Metrics
Neurocrine Biosciences, Inc. has adjusted its valuation, showcasing a P/E ratio of 36 and a price-to-book value of 5.20. With strong operational efficiency reflected in a ROCE of 28.21% and a one-year return of 13.16%, the company maintains a competitive edge in the Pharmaceuticals & Biotechnology sector.
Is Neurocrine Biosciences, Inc. overvalued or undervalued?
As of November 21, 2025, Neurocrine Biosciences, Inc. has an attractive valuation grade, indicating it is undervalued with a favorable P/E ratio of 35 and strong ROCE of 30.61%, although it has underperformed the S&P 500 over the past 3 and 5 years despite a recent 1-year return of 12.42%.
Is Neurocrine Biosciences, Inc. overvalued or undervalued?
As of November 21, 2025, Neurocrine Biosciences, Inc. is considered an attractive investment due to its undervalued stock, strong fundamentals with a P/E ratio of 35, an EV to EBITDA of 21.72, and a robust ROCE of 30.61%, despite recent underperformance compared to the S&P 500.
Is Neurocrine Biosciences, Inc. technically bullish or bearish?
As of October 31, 2025, Neurocrine Biosciences, Inc. shows a bullish technical trend overall, supported by daily moving averages and monthly MACD, but with caution due to mixed signals from weekly indicators and underperformance against the S&P 500 in the longer term.
Is Neurocrine Biosciences, Inc. technically bullish or bearish?
As of October 31, 2025, Neurocrine Biosciences, Inc. shows a bullish trend overall, supported by daily moving averages and monthly MACD, but mixed signals from weekly indicators, while it has underperformed the S&P 500 with returns of 16.16% and 14.38% over the past year and three years, respectively.
Is Neurocrine Biosciences, Inc. technically bullish or bearish?
As of October 31, 2025, Neurocrine Biosciences, Inc. shows a bullish technical trend supported by daily moving averages and Bollinger Bands, despite mixed short-term signals from weekly indicators and underperformance compared to the S&P 500 over various time frames.
Is Neurocrine Biosciences, Inc. technically bullish or bearish?
As of October 31, 2025, Neurocrine Biosciences, Inc. shows a bullish technical trend overall, supported by daily moving averages and On-Balance Volume, but with caution due to mixed short-term signals and underperformance compared to the S&P 500.
Neurocrine Biosciences Experiences Revision in Stock Evaluation Amid Strong Market Performance
Neurocrine Biosciences, Inc. has recently experienced a revision in its evaluation amid fluctuating market conditions. The stock has demonstrated strong performance metrics, outpacing the S&P 500 over various time frames. Technical indicators show a predominantly bullish sentiment, although some mixed signals are present in the short term.
Is Neurocrine Biosciences, Inc. technically bullish or bearish?
As of October 24, 2025, Neurocrine Biosciences, Inc. shows a bullish trend with strong indicators, outperforming the S&P 500 recently, though it has underperformed over longer periods.
Is Neurocrine Biosciences, Inc. technically bullish or bearish?
As of October 24, 2025, Neurocrine Biosciences, Inc. has a bullish trend supported by strong indicators, although it has underperformed the S&P 500 over the longer term despite a recent weekly outperformance.
Is Neurocrine Biosciences, Inc. technically bullish or bearish?
As of October 24, 2025, Neurocrine Biosciences, Inc. has a bullish trend supported by strong indicators, although mixed signals from KST and Dow Theory suggest caution, while the stock has outperformed the S&P 500 in the short term but lags in longer periods.
Is Neurocrine Biosciences, Inc. overvalued or undervalued?
As of October 17, 2025, Neurocrine Biosciences, Inc. is considered overvalued with a valuation grade of expensive, reflected in its high P/E ratio of 35 and underperformance over five years compared to the S&P 500, despite a recent 18.26% return over the past year.
Neurocrine Biosciences Experiences Revision in Its Stock Evaluation Amid Strong Market Performance
Neurocrine Biosciences, Inc. has recently adjusted its valuation, with its current price at $140.09. The company has achieved an 18.26% return over the past year, outperforming the S&P 500. Key metrics indicate strong profitability and a premium valuation compared to industry peers, reflecting its competitive position.
Is Neurocrine Biosciences, Inc. overvalued or undervalued?
As of October 17, 2025, Neurocrine Biosciences, Inc. is considered overvalued with a valuation grade shift from fair to expensive, reflected by a high P/E ratio of 35 and mixed industry performance, despite a short-term stock return of 18.26% compared to the S&P 500's 14.08%.
{{list.post_title}}
{{list.post_excerpt}}
{{list.post_title}}
{{list.post_excerpt}}
